Company profile: Myelo Therapeutics
1.1 - Company Overview
Company description
- Provider of treatments addressing high unmet medical needs, focused on developing myelo001, a small molecule effective on hematogenesis and investigated for its oral application in treating chemotherapy-induced myelosuppression, radiation-induced myelosuppression, and acute radiation syndrome. Founded in 2013 and based in Berlin, Germany.
Products and services
- Hematogenesis Therapeutics Focus: Produces treatment approach effective on hematogenesis to help counter chemotherapy-induced myelosuppression, radiation-induced myelosuppression, and acute radiation syndrome via an oral small-molecule modality
- Innovative Treatments Development: Development-focused program that creates therapies for high unmet medical needs across a range of medical indications, architecting novel medicine candidates from Berlin, Germany
- Myelo001: Investigational small molecule effective on hematogenesis, engineered for oral administration to mitigate chemotherapy- and radiation-induced myelosuppression and address acute radiation syndrome.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Myelo Therapeutics
C4X Discovery
HQ: United Kingdom
Website
- Description: Provider of NMR-based 3D molecular structure determination to optimize drug design and development, partnering with pharma to generate better, safer products. Offers Conformetrix 4D structural design technology, 4Sight visualizer, PatientSeek for genetic patient stratification, and programs including oral α4β7 integrin inhibitors, IL-17A inhibitors (licensed to Sanofi), and NRF2 activators (licensed to AstraZeneca).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C4X Discovery company profile →
Valerio Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology therapeutics leveraging the platON chemistry platform to generate DNA-decoy compounds targeting intracellular DNA-binding proteins for tumors and inflammatory diseases; develops AsiDNA and VIO-01 to disrupt DNA repair and activate the STING pathway, and Belinostat/Beleodaq, a histone deacetylase inhibitor for hematological and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valerio Therapeutics company profile →
Sapience Therapeutics
HQ: United States
Website
- Description: Provider of novel peptide therapeutics addressing major unmet medical needs, including ST101, a peptide antagonist targeting C/EBPβ in Phase 2 for advanced solid tumors such as recurrent GBM, and ST316, a first-in-class peptide antagonist of β-catenin entering Phase 1-2 for solid tumors with Wnt/β-catenin pathway abnormalities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sapience Therapeutics company profile →
Cabrellis
HQ: United States
Website
- Description: Provider of specialty pharmaceutical cancer therapy development, planning three small cell lung cancer clinical trials in 2006, including a study assessing the safety and efficacy of Calsed(TM) in reference to topotecan for second-line treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cabrellis company profile →
Olaris
HQ: United States
Website
- Description: Provider of metabolomics and machine learning-based disease diagnosis and treatment solutions, including Olaris CEREBRO for metabolite profiling to identify individual molecular profiles, myOLARIS diagnostics, a suite of in vitro diagnostic products to optimize patient-specific treatments and outcomes, and Biomarkers of Response (BoRs) technology to determine which patients will benefit from specific therapies and reduce adverse events.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Olaris company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Myelo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Myelo Therapeutics
2.2 - Growth funds investing in similar companies to Myelo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Myelo Therapeutics
4.2 - Public trading comparable groups for Myelo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →